Expanding into Additional Rare and Major Diseases

Synlogic’s platform is equally applicable to both rare and more common diseases and additional indications are being pursued, enabled by our increased understanding of the microbiome. We will leverage the well-established science linking the microbiome with metabolic dysregulation in a wide range of conditions, including autoimmune, metabolic, cardiovascular, oncology and CNS diseases.

Emerging solid scientific data indicate that the microbiome can be considered a distinct human organ, composed of groups of microbes that carry out certain essential metabolic activities. Our Synthetic BioticTM medicines can function as a new group of enhanced probiotic bacteria, blending with the existing flora to add new metabolic and immune functions. The new functions that we build in our platform are based upon decades of scientific inquiry that has linked metabolic and immunological dysregulation with disease.

Examples of key activities that our therapeutic approach can address include:

  • short chain fatty acid synthesis and degradation
  • branched chain amino acid catabolism
  • toxic metabolite metabolism
  • secreted or displayed cytokines, chemokines, enzymes, and immune regulatory antibodies

By programming Synthetic Biotic medicines to perform multiple activities, we have the opportunity to correct a dysfunctional somatic organ by shifting its function to an augmented microbiome. Additionally, our Synthetic Biotic medicines can provide regulation to a dysregulated immune state.

Synlogic is applying this approach to develop Synthetic Biotic medicines in its own programs and in partnership with pharmaceutical companies. We are currently working with our partner, AbbVie, to create innovative Synthetic Biotic medicines for the treatment of certain forms of inflammatory bowel disease (IBD) such as Crohn’s disease and ulcerative colitis.